David Dalvey Sells 100,000 Shares of Celcuity, Inc. (NASDAQ:CELC) Stock

Key Points

• Director Transaction: Celcuity, Inc. director David Dalvey sold 100,000 shares at an average price of $43.98, totaling $4.4 million, reducing his ownership by 44.44%.
• Price Performance: Celcuity's stock is currently trading at $40.30, with a one-year range between $7.57 and $46.42, and a market capitalization of $1.53 billion.
• Analyst Ratings: Celcuity has a consensus "Buy" rating with target prices ranging from $29.00 to $60.00, as reported by several investment firms recently.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) Director David Dalvey sold 100,000 shares of the stock in a transaction on Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the completion of the sale, the director directly owned 125,000 shares of the company's stock, valued at $5,497,500. The trade was a 44.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

David Dalvey also recently made the following trade(s):

• On Monday, July 28th, David Dalvey sold 9,325 shares of Celcuity stock. The shares were sold at an average price of $45.12, for a total value of $420,744.00.

Celcuity Stock Performance

CELC stock traded up $0.74 during midday trading on Friday, hitting $39.91. The company's stock had a trading volume of 1,549,488 shares, compared to its average volume of 2,299,647. The stock's 50-day moving average price is $15.25 and its 200 day moving average price is $12.29. The company has a quick ratio of 6.61, a current ratio of 6.61 and a debt-to-equity ratio of 1.14. Celcuity, Inc. has a 1 year low of $7.57 and a 1 year high of $46.42. The stock has a market cap of $1.55 billion, a price-to-earnings ratio of -13.17 and a beta of 0.67.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.09. On average, equities analysts forecast that Celcuity, Inc. will post -2.62 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Summit Investment Advisors Inc. lifted its position in shares of Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock valued at $45,000 after buying an additional 1,132 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in shares of Celcuity during the 4th quarter valued at $50,000. AlphaQuest LLC lifted its position in shares of Celcuity by 176.3% during the 2nd quarter. AlphaQuest LLC now owns 7,087 shares of the company's stock valued at $95,000 after buying an additional 4,522 shares during the last quarter. Focus Financial Network Inc. purchased a new position in shares of Celcuity during the 1st quarter valued at $108,000. Finally, Perkins Capital Management Inc. purchased a new position in shares of Celcuity during the 1st quarter valued at $115,000. Hedge funds and other institutional investors own 63.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on CELC shares. Needham & Company LLC reissued a "buy" rating and issued a $29.00 price target on shares of Celcuity in a research report on Monday, July 28th. Stifel Nicolaus assumed coverage on Celcuity in a research report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price target for the company. Leerink Partners boosted their price objective on Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research report on Monday, July 28th. Finally, HC Wainwright boosted their price objective on Celcuity from $27.00 to $50.00 and gave the stock a "buy" rating in a research report on Monday, July 28th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $39.20.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.